Introduction
Signal transduction through CD28 plays an important role in regulating the initial response of a T cell to antigen. Two distinct CD28 ligands, B7-1 (CD80) and B7-2 (CD86), have been identified. These ligands also bind to CTLA-4, a receptor closely related to CD28 that is expressed on activated T cells. Recent studies designed to examine the individual roles of B7-1 and B7-2 in the regulation of an in vivo immune response have demonstrated that costimulation through CD28, CTLA-4, or both is more complex than previously believed. In vivo, the costimulatory ligands B7-1 and B7-2 appear to differ in their ability to potentiate the differentiation of T helper (Th) cells into either type 1 (Thl) cells, which direct cell-mediated immunity, or type 2 (Th2) cells, which support a humoral immune response. These results have important implications for our understanding of in vivo immune responses as well as for strategies of immunotherapy involving the CD28 costimuiatory pathway.
The Role of Costimulatory Receptors in the Initiation of an immune Response
An antigen-specific T cell immune response is initiated as a result of interaction between a T cell receptor (TCR) and antigen-major histocompatibility complex (MHC) complexes expressed on the surface of an antigen-presenting cell (APC). However, while TCR signal transduction is necessary for the activation of a naive T cell, TCR ligation alone is not sufficient to initiate an immune response under most circumstances (Figure 1 ). For optimal activation of a naive T cell, additional or costimulatory signals are needed. Activation through the TCR in the presence of such costimulatory signals results in T cell clonal expansion and in the induction of effector functions such as lymphokine production. Interaction of naive T cells with antigen in the absence of a costimulatory signal can result in T cell unresponsiveness or death. In this model, T cell costimulatory signals play a critical role in dictating the subsequent fate of a T cell that initiates a response to antigen. The BZICD28 Activation Pathway Transmits a Costimulatory Signal Work over the last several years has demonstrated that CD28 is one of the major costimulatory receptors on the surface of a resting T cell (for review see Allison, 1994) . Signal transduction through CD28 synergizes with TCR signal transduction to augment both interleukin-2 (IL-2) production and proliferation of naive T cells. Blockade of the CD28 signal transduction pathway by noncross-linking monovalent antibody fragments can render T cells hyporesponsive to subsequent challenge with antigen. Several years ago, the B cell activation antigen B7-1 (CD80) was found to be a ligand for CD28. B7-1 was subsequently found to be expressed as an activation antigen on a variety of additional APCs, including dendritic cells and monocytes.
In addition to CD28, B7-1 can bind to the T cell activation antigen CTLA-4. CTLA-4 binds to B7-1 with -20-fold higher avidity than CD28. In contrast with°CD28, CTLA-4 is not expressed on quiescent T cells, but CTLA-4 expression is detectable following TCR ligation and can be further augmented by CD28 costimulation. At present, the role of CTLA-4 in costimulation is uncertain. Depending on the circumstances, CTLA-4 has been reported to act as an additional costimulatory signal or to act as a negative signal to down-mod ulate an immune response either by terminating a proliferative response or directly inducing apoptosis. A soluble recombinant form of CTLA-4, CTLA41g, has been used as a competitive inhibitor of CD28 activation. In vivo, CTLA41g treatment can suppress the ability to mount T cell-dependent antibody production as well as suppress the ability to mount a cell-mediated immune response against tissue grafts.
The demonstration that CTLA41g could inhibit T celldependent immune responses that were not inhibited by B7-1 antibodies, as well as the recognition that mice deficient in B7-1 could still induce CD28 costimulation, resulted in the discovery of a second ligand for the CD28 receptor, B7-2. Although B7-2 shares only 26% amino acid identity with B7-1, B7-2 is also a member of the immunoglobulin gene superfamily and appears to be (~losely linked in the genome to B7-1. B7-2 displays a different pattern of expression from that of B7-1. B7-2 is rapidly induced on the surface of activated B cells or monocytes and is expressed at high levels on dendritic cells. Its kinetics of induction suggest that B7-2 is the major CD28 ligand expressed early during an immune response.
Activated Th Cells Can Differentiate into Distinct Types of Effector Cells
One unexplained aspect of the B7/CD28 activation pathway is the reason there is redundancy of both the receptors . and the ligands in the B7/CD28 pathway(s). Experiments designed to examine the differential roles of the individual ligands are now being reported, and the early reports are startling. Kuchroo et al. (1995) and Lenschow et al. (1995) have l"eported evidence that isolated blockade of B7-1 or B7-2 in vivo does not inhibit the ability to initiate an immune response but rather affects the type of immune response that develops by altering the differentiation of Th cells. CD4 ÷ Th cells can differentiate into either of two distinct types of effector cells: Thl cells, which regulate cellmediated immunity, and Th2 cells, which regulate humoral immune responses (for review see Paul and Seder, 1994) . Each of these two Th cell subtypes produces a distinct set of regulatory cytokines. Thl cells produce IL-2, y-interferon (IFNy), and tumor necrosis factor J3, while Th2 cells produce IL-4, IL-5, and IL-10. The differentiation of naive Th cells into Thl and Th2 cells has important implications in the immune response. In several models of autoimmune disease, a Th2 immune response is associated with disease resistance while induction of a Thl response leads to progressive disease. In contrast, protective immunity from intracellular pathogens such as Leishmania major requires a Thl response, while a Th2 response results in progressive disease.
The molecular bases for the differentiation of Th cells are just beginning to be delineated (Figure 2) . Activation of precursor Th cells results in the production of IL-2 with relatively little IFNy or IL-4 being produced (Th0). Subsequent events appear to bias the cell toward differentiation into a Thl or Th2 phenotype. The most effective inducers of such differentiation appear to be IL-12 and IL-4. Under the influence of I L-4, precursor cells differentiate preferentially down the Th2 pathway, while in the presence of IL-12, cells differentiate down the Th 1 pathway. Subsequent activation of these differentiating cells by antigen reinforces these differentiation events since Th2 cells preferentially produce IL-4 and Thl cells produce IFNy. These lymphokines in turn help perpetuate humoral and cellular immu ne responses, respectively.
Several types of immune cells have been shown to be able to produce IL-4 during an immune response, including the NKI.1 subset of T cells and mast cells. IL-12 appears to be produced primarily by monocytes, but several other cell types, including dendritic cells and keratinocytes, can produce IL-12. The provision of either IL-12 or IL-4 by the APC plays a strong role in biasing Th cell differentiation. However, even in the absence of exogenous lymphokines, T cells can be directed to either Thl or Th2 differentiation (Kalinski et at., 1995) . High doses of antigen appear to favor differentiation down the Th2 pathway, while low antigen doses appear to favor a Thl response (Bretscher et al., 1992) . The route of antigen administration also appears to play an important role, perhaps through the recruitment of distinct populations of APCs . Costimulation by B7.1 and B7.2 Can Differentially Regulate Th Cell Differentiation Kuchroo et al. (1995) have now presented evidence that B7-1 and B7-2 may play distinct roles in the differentiation of Th cells. These investigators studied experimental allergic encephalomylitis induced by immunization with proteolipid protein in animals simultaneously treated with either anti-B7-1 or anti-B7-2. Treatment with anti-B7-1 resulted in the generation of effector T cells that had a Th2 phenotype. These Th2 cells could both prevent the induction of experimental allergic encephalomylitis and abrogate established disease. In contrast, treatment with anti-B7-2 resulted in the production of effector cells of a Thl phenotype, resulting in increased disease severity. These data suggest that not only is costimulation important during the initial activation of uncommitted Th cells, but that costimulation may also play a crucial role in regulating the subsequent differentiation of Th0 cells along the Thl or Th2 developmental pathways.
Other groups have also begun to report that differential blockade of B7-1 or B7-2 can have distinct effects on in vivo immune responses. Lenschow et al. (1995) have studied the role of B7-1 and B7-2 antibodies on the development of autoimmune diabetes in the NOb mouse strain. Anti-B7-2 prevented the onset of diabetes, while treatment with anti-B7-1 resulted in an increased incidence and an accelerated course of diabetes.
Although the findings by Kuchroo et al. (1995) and Lenschow et al. (1995) may initially seem contradictory, both studies suggest that costimulation plays a role in the differentiation of Th cells. Further support for this hypothesis can be drawn from observations that Thl and Th2 responses display differences in their dependence on costimulation (Lu et al., 1994; McKnight et al., 1994; King et al., 1995) . For example, Corry et al. (1994) have studied the effect of CTLA41g treatment on the response of different mouse strains to L. major infection. In mice that are genetically predisposed to produce the Thl response to L. major, induction of the Thl response is not affected by CTLA41g treatment. This suggests that this response can occur under conditions of either low or no costimulation. In contrast, the ability of susceptible mouse strains to mount a Th2 response can be blocked by CTLA41g.
Potential Mechanisms for the Differential Regulation of Thl/Th2 Development by B7.1 and B7.2
There are several mechanisms by which the two costimulatory ligands may have a differential effect on Th cell differentiation. Based on the relative timing of their expression, B7-2 may be the physiologic ligand for CD28, while B7-1 is primarily a ligand for CTLA-4. However, failed to find evidence for differential pairing of the proteins. They found that B7-1 and B7-2 display similar avidity for CD28. Both B7-1 and B7-2 display higher avidity for CTLA-4, although B7-2 binding to CTLA-4 displays more rapid dissociation kinetics than B7-1. An alternative possibility suggested by Kuchroo et al. (1995) is that B7-1 and B7-2 engage CD28 in distinct ways that result in differences in receptor signal transduction. Nun,bs et al. (1994) have shown that differential signal transduction through CD28 can occur. Antibodies that cross-link CD28 induce activation of Ras, while costimulation by B7-1-transfected cells does not appear to induce Ras activation. As suggested by Lenschow et al. (1995) , differences in B7-1-and B7-2-induced signal transduction could also be due to differential signaling through CTLA-4. Studies involving animals with a germline deficiency in CTLA-4 may help to resolve this issue.
There is some evidence against a role for differential signal transduction in explaining the differences between B7-1 and B7-2 costimulation. Two groups that have examined the effects of signal transduction using B7-1 and B7-2 transfectants have failed to find any significant differences in the activation of second messengers or lymphokine production (Lanier et al., 1995; Levine et al., 1995) . While Freeman et al. (1995) have demonstrated that multiple rounds of antigen priming by B7-2-transfected cells can lead to a Th2 phenotype, Seder et al. (1994) have used B7-1-expressing cells to induce the development of Th2 clones. These data suggest th at there is no absolute difference in B7-1-and B7-2-initiated signaling.
There are several additional possibilities for the differential ability of B7-1 and B7-2 to affect Th cell differentiation. There are clear differences both in the timing of the expression of B7-1 and B7-2 during an immune response as well as differences in their expression on different APCs (Hathcock et al., 1994) . Antibody blocking experiments suggested that B7-2 is the major CD28 ligand that initiates CD28-dependent costimulation in unprimed lymph node cells. In contrast, B7-1 costimulation appears to be up: regulated later during activation of an immune response, and has been proposed to be the major costimulatory ligand present during persistent infections. Distinct roles for B7-1 and B7-2 may also result from differences in their relative expression on the APCs involved in T cell differentiation (Figure 2) .
B7-1 and B7-2 could also serve as counterreceptors that transduce distinct signals to the APC upon engagement by CD28 or CTLA-4. The intracellular domains of B7-1 and B7-2 are quite distinct and could mediate differential signal transduction. Such signaling could alter the APC's ability to function as an effector cell. Delineation of these possibilities may come from characterization of mice with germline deletions of the B7-1 gene, the B7-2 gene ~, or both.
Thl and Th2 Cells Differ in their Requirements for Costimulation
Experiments to define the parameters that control Th2 development have suggested that Th2 immune responses are dependent on high initial antigen doses. Th2 immune responses also appear to be dependent on CD28 costimulation during their initiation, but thereafter appear to be relatively less dependent on costimulation for their maintenance (McKnight et al., 1994) . A potential mechanism for this is the observation that CD28 costimulation is necessary for the induction of T cell sensitivity to IL-4 (McArthur and Raulet, 1993) . Thus, CD28 costimulation is essential for initiating a state of responsiveness to induction of Th2 differentiation by IL-4, but is not necessary for the maintenance of the Th2 state. In contrast, the initiation of Thl responses appears to be less dependent on CD28 costimulation. Thl responses can be generated in CD28-deficient animals or in animals in which CD28 costimulation is blocked by CTLA41g (Shahinian et al., 1993; Green et al., 1994) . However, Thl immune responses, even when established, appear to be sensitive to modulation by CD28 costimulation. Most established Thl clones~continue to require CD28 costimulation for activation (Allison, 1994) . These observations suggest that B7-2, by being the primary costimulatory ligand present in unprimed animals, may play a more critical role in the ability to initiate a Th2 response, while B7-1, with its later kinetics of induction, may be more important in the maintenance of Thl responses. Consistent with this hypothesis, Sayegh et al. (1995) have shown that delaying CTLA41g treatment until 48 hr after renal allografting selectively spares a protective Th2 response while still inhibiting a Thl response.
A possible model for how CD28 costimulation could affect the initial commitment of a naive Th cell is one in which Thl/Th2 differentiation is determined by the strength of the activation signal (Figure 3) . Depending on the initial antigen dose, CD28 costimulation could shift the response to antigenic challenge from no response to aThl response or from a Thl response to a Th2 response. Depending on when a naive T cell is recruited into an ongoing immune response and the type of APC involved, the major costim ulatory ligand could shift from B7-2 to B7-1. Such a model has the potential to explain some of the seemingly paradoxical responses observed in response to blocking B7-1 and B7-2 in vivo. For example, a destructive Thl response could either be prevented at low antigen doses by blocking CD28 costimulation or be shifted to a protective Th2 response at high antigen doses by augmenting costimulation. In addition, a protective Th2 response that is dependent on costimulation could be shifted to either a pathogenic Thl response or no response by blocking costimulation.
BZICD28 Costimuletion in the Maintenance of Established Immune Responses
While the activation of naive T cells is critically dependent on costimulatory signals, memory T cells are less dependent on costimulation for activation (Croft et al., 1994) . These data have been interpreted to suggest that blocking B7-1/B7-2 costimulation would be relatively ineffective at blocking established or recall immune responses. One recent set of data that appears difficult to reconcile with the above observations is the ability of CTLA41g to block established autoimmune disease in NZB/NZW mice. These mice are studied as a murine model of systemic lupus erythematosus, a disease that results from the production of autoantibodies. B cell production of autoantibodies is believed to be dependent on Th2 cells. Finck et al. (1994) have demonstrated that CTLA41g treatment not only prevents the development of disease but can also abrogate disease in animals with established autoimmunity. This result would seem to contradict the proposal that costimulation is required during the initiation but not the maintenance of a Th2 immune response. However, recent studies of autoimmunity have suggested that autoimmune disease results in the sequential activation of autoreactive clones with differing specificities, a process referred to as epitope spreading. Thus, some autoimmune diseases may be perpetuated through the sequential activation of naive T cells responding to distinct autoantigens exposed during ongoing immune destruction. If this is the case, CTLA41g may block established disease by inhibiting the ongoing differentiation of cells into the Th2 lineage rather than by inhibiting established Th2 clones.
In summary, the B7/CD28 costimulatory pathway plays a complex role in regulating in vivo immune responses. In addition to augmenting the lymphokine production and initial proliferation of naive T cells, the B7/CD28 costimulatory pathway also appears to play an important role in regulating the differentiation of Th cells into Thl or Th2 cells. A clearer understanding of these additional roles for the CD28/CTLA-4 receptors and the differential ways in which B7-1 and B7-2 affect these aspects of immune activation will have important implications for immunotherapy.
